News
Francesc Posas: “Basic research allows designing more accurate clinical applications”
“Understanding how cells respond to stress, how they realize that there is a dangerous situation and how they put in place the mechanisms to respond.” This is one of the objectives of the laboratory run by Francesc Posas in the Universitat Pompeu Fabra. More specifically, study the functions of these kinases in stress response mechanisms. …
Francesc Posas: “Basic research allows designing more accurate clinical applications” Read More »
Emilià Pola: ”2011 has been the best year of IDIBELL, at the worst economic period”
With this sentence the general director of IDIBELL, Emilià Pola, has summarized the general situation of the institution: our scientific production has increased, and also our impact, and we have more competitive projects. On the other side of the scales, the economic crisis means that there is less support and less amount, and it complicates …
Emilià Pola: ”2011 has been the best year of IDIBELL, at the worst economic period” Read More »
Manel Esteller, I National Award in Cancer Research ‘Doctores Diz Pintado’
The director of the Cancer Epigenetics and Biology program at IDIBELL and professor of the University of Barcelona, Manel Esteller, has won the ‘I National Award for Research on Cancer Doctores Diz Pintado’ for his scientific career, awarded by the Cancer Research Foundation of the University of Salamanca (Ficus). The award was granted to Esteller …
Manel Esteller, I National Award in Cancer Research ‘Doctores Diz Pintado’ Read More »
Pedro Montoya: “Chronic pain not only hurts, it also damages the brain”
The researcher Peter Montoya and his team at the University of the Balearic Islands are investigating how brain function changes in patients with chronic pain compared with brain activity in healthy subjects. He explained his latest results on 20 January in the series of seminars IDIBELL. “We do not know how the fire occurs; we …
Pedro Montoya: “Chronic pain not only hurts, it also damages the brain” Read More »
Anna Veiga: ”We need very safe iPS cells if we want to use them in the clinic”
The researcher of the Center for Regenerative Medicine in Barcelona, CMR[B], Anna Veiga, explained the latest developments of her research group on “in vitro” models of pluripotency in embryonic stem cells (hESCs) and iPS cells ( induced pluripotent stem cells). It was on January 13 in the cycle of seminars IDIBELL. Since 2005 Veiga directs …
Anna Veiga: ”We need very safe iPS cells if we want to use them in the clinic” Read More »
Manel Esteller, International Research Award of Fundación Dexeus, Women’s Health
Manel Esteller, director of the Epigenetics and Cancer Biology Program at IDIBELL, Professor of Genetics at the University of Barcelona and ICREA Research Professor has been awarded with the International Research Award of Fundación Dexeus, Women’s Health in its eighth edition. The award honors a person whose career and continuing line of research constitutes a …
Manel Esteller, International Research Award of Fundación Dexeus, Women’s Health Read More »
The program Stromalign receives 1.5 million Euros from the European Research Council
The European Research Council (ERC) has awarded with a Starting Grant for scientific excellence Oriol Casanovas, researcher at IDIBELL and at the Catalan Institute of Oncology for the project ‘Mechanisms and Targeting Stromal Tumor Invasion Contribution tone and Metastasis’. The funded project, called Stromalign, focuses on the study of tumor stroma as a possible major …
The program Stromalign receives 1.5 million Euros from the European Research Council Read More »
IDIBELL edits a calendar of world health awareness days
Bellvitge Biomedical Research Institute (IDIBELL) has published a calendar that includes the world health awareness days established by the World Health Organization and other international institutions. The calendar expresses IDIBELL’s will to guide its research activities on improving people’s health.
Luis Pérez-Jurado, ”losartan gives good results for treating heart problems in Williams-Beuren syndrome”
Losartan, a drug used against high blood pressure, is an effective treatment for cardiac complications of the cardiovascular phenotype of Williams-Beuren syndrome. This is the result of a recent clinical trial coordinated by the researcher Luis Pérez-Jurado, of the University Pompeu Fabra University and CIBER of Rare Diseases. Pérez-Jurado spoke about the study and the …